×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BCAB – bioatla, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BCAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
12:25 am
bcab
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
High
Report
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
11/14
07:08 pm
bcab
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]
High
Report
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]
11/13
06:54 pm
bcab
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]
High
Report
BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]
11/13
06:52 pm
bcab
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/7
09:00 am
bcab
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
Low
Report
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
11/5
08:00 am
bcab
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
Medium
Report
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
10/23
08:00 am
bcab
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
Low
Report
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
10/20
08:00 am
bcab
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
High
Report
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/1
06:37 pm
bcab
Form 4 BioAtla, Inc. For: Nov 30 Filed by: WALDRON RICHARD A
Medium
Report
Form 4 BioAtla, Inc. For: Nov 30 Filed by: WALDRON RICHARD A
12/1
06:35 pm
bcab
Form 4 BioAtla, Inc. For: Nov 30 Filed by: SHORT JAY M PHD
Medium
Report
Form 4 BioAtla, Inc. For: Nov 30 Filed by: SHORT JAY M PHD
12/1
06:35 pm
bcab
Form 4 BioAtla, Inc. For: Nov 30 Filed by: Vasquez Christian
Medium
Report
Form 4 BioAtla, Inc. For: Nov 30 Filed by: Vasquez Christian
12/1
06:35 pm
bcab
Form 4 BioAtla, Inc. For: Nov 30 Filed by: Sievers Eric
Medium
Report
Form 4 BioAtla, Inc. For: Nov 30 Filed by: Sievers Eric
11/24
11:16 am
bcab
Form PRE 14A BioAtla, Inc. For: Nov 24
Medium
Report
Form PRE 14A BioAtla, Inc. For: Nov 24
11/21
06:15 am
bcab
Form 8-K BioAtla, Inc. For: Nov 20
High
Report
Form 8-K BioAtla, Inc. For: Nov 20
10/15
08:37 am
bcab
Form SCHEDULE 13G BioAtla, Inc. Filed by: OPOKA INVESTMENT FUND Co
Low
Report
Form SCHEDULE 13G BioAtla, Inc. Filed by: OPOKA INVESTMENT FUND Co
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: